· The CHMP positive opinion marks the first time a monoclonal antibody treatment for COVID-19 has received a recommendation for marketing authorisation from the EMA
· The recommendation is based on data from the global Phase III clinical trial investigating regdanvimab as a treatment for multiple variants of COVID-19, including the Delta variant
· Regdanvimab is the first authorised COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS); More than 21,366 people treated with regdanvimab in 127 hospitals in the Republic of Korea
INCHEON, Korea, Nov 15 (Bernama-BUSINESS WIRE) — Celltrion Group announced today that the European Medicine’s Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion recommending marketing authorisation for regdanvimab (CT-P59), a monoclonal antibody treatment for adults with COVID-19 that do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. The CHMP positive opinion is a scientific recommendation to the European Commission (EC), which authorises marketing approval in the European Union.
- WHO urges 50pct price hike on tobacco and alcohol by 2035
- Egyptian, Ukrainian Leaders Discussed Russia-Ukraine Conflict, Regional Developments
- Iran Still Needs More Time To Decide On Resuming Talks With U.S.: FM
- World will have to learn to live with heatwaves: UN
- US: Colorado woman dies weeks after firebombing at Gaza hostage protest
- Afghan Ministry Signs MoU To Assist Returnees, Poor
- Cambodia, Singapore Vowed To Further Enhance Ties, Cooperation
- Vietnam’s Party Chief Welcomed New Trade Deal With U.S.
- Explainer: Why Was Thai PM Paetongtarn Suspended From Duty?
- S. Korea’s Top Prosecutor Offers To Resign